Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Knutson, Sarah K ^a   Warholic, Natalie M ^a   Johnston, L Danielle ^a   Klaus, Christine R ^a   Wigle, Tim J ^a   Iwanowicz, Dorothy ^a   Littlefield, Bruce A ^b   Porter Scott, Margaret ^a   Smith, Jesse J ^a   Moyer, Mikel P ^a,c   Copeland, Robert A ^a   Pollock, Roy M ^a   Kuntz, Kevin W ^a   Raimondi, Alejandra ^a   Keilhack, Heike ^a  

^a EPIZYME INC   (United States)

^b EISAI INC   (United States)

^c Loxo Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME INHIBITOR; EPZ 6438; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; BENZAMIDE DERIVATIVE; DEXAMETHASONE; EPZ-6438; EZH2 PROTEIN, HUMAN; EZH2 PROTEIN, MOUSE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PYRIDONE DERIVATIVE; TRANSCRIPTION FACTOR EZH2; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE CONTROL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; TUMOR GROWTH; TUMOR VOLUME; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; LYMPHOMA, NON-HODGKIN; METABOLISM; PRECLINICAL STUDY; RANDOMIZATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; HUMANS; LYMPHOMA, NON-HODGKIN; MICE, SCID; NEOPLASM TRANSPLANTATION; PREDNISOLONE; PREDNISONE; PYRIDONES; RANDOM ALLOCATION; RECEPTORS, GLUCOCORTICOID; VINCRISTINE;

EID: 84916881910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111840     Document Type: Article

References (42)

1. Furusawa C, Kaneko K (2012) A dynamical-systems view of stem cell biology. Science 338: 215-217.
2. Clements WK, Traver D (2013) Signalling pathways that control vertebrate haematopoietic stem cell specification. Nat Rev Immunol 13: 336-348.
3. Badeaux AI, Shi Y (2013) Emerging roles for chromatin as a signal integration and storage platform. Nat Rev Mol Cell Biol 14: 211-224.
4. Copeland RA, Solomon ME, Richon VM (2009) Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8: 724-732.
5. Schenone M, Dancik V, Wagner BK, Clemons PA (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9: 232-240.
6. Wigle TJ, Copeland RA (2013) Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. Curr Opin Chem Biol 17: 369-378.
7. Oakley RH, Cidlowski JA (2013) The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 132: 1033-1044.
8. Copeland RA, Moyer MP, Richon VM (2013) Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene 32: 939-946.
9. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
10. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105: 13520-13525.
11. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, et al. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15: 5494-5502.
12. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282.
13. Niitsu N (2010) Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol 92: 231-237.
14. Nastoupil LJ, Rose AC, Flowers CR (2012) Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park) 26: 488-495.
15. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, et al. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181-185.
16. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303.
17. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, et al. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 109: 3879-3884.
18. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, et al. (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8: 890-896.
19. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, et al. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112.
20. Qi W, Chan H, Teng L, Li L, Chuai S, et al. (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 109: 21360-21365.
21. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, et al. (2013) An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 8: 1324-1334.
22. Garapaty-Rao S, Nasveschuk C, Gagnon A, Chan EY, Sandy P, et al. (2013) Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol 20: 1329-1339.
23. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, et al. (2014) Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma. Mol Cancer Ther 13: 842-854.
24. Ramamoorthy S, Cidlowski JA (2013) Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. Endocr Dev 24: 41-56.
25. Budanov AV, Karin M (2008) p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134: 451-460.
26. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, et al. (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23: 677-692.
27. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, et al. (2009) Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 20: 816-827.
28. Maxwell SA, Mousavi-Fard S (2013) Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp Biol Med (Maywood) 238: 971-990.
29. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, et al. (2013) Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24: 777-790.
30. Lenz G, Nagel I, Siebert R, Roschke AV, SangerW, et al. (2007) Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 204: 633-643.
31. Rutz HP (2002) Effects of corticosteroid use on treatment of solid tumours. Lancet 360: 1969-1970.
32. Rutz HP, Herr I (2004) Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther 3: 715-718.
33. Sionov RV, Spokoini R, Kfir-Erenfeld S, Cohen O, Yefenof E (2008) Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv Cancer Res 101: 127-248.
34. Schlossmacher G, Stevens A, White A (2011) Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 211: 17-25.
35. George AA, Schiltz RL, Hager GL (2009) Dynamic access of the glucocorticoid receptor to response elements in chromatin. Int J Biochem Cell Biol 41: 214-224.
36. John S, Sabo PJ, Johnson TA, Sung MH, Biddie SC, et al. (2008) Interaction of the glucocorticoid receptor with the chromatin landscape. Mol Cell 29: 611-624.
37. Van Bogaert T, De Bosscher K, Libert C (2010) Crosstalk between TNF and glucocorticoid receptor signaling pathways. Cytokine Growth Factor Rev 21: 275-286.
38. van Horssen R, Ten Hagen TL, Eggermont AM (2006) TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408.
39. Ayroldi E, Riccardi C (2009) Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 23: 3649-3658.
40. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, et al. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53-65.
41. Copeland RA (2013) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. Hoboken, NJ: John Wiley & Sons Inc. 538 p.
42. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, et al. (2013) Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 110: 7922-7927.